Complete Conference Coverage Archive

Two Additions to Standard of Care in Prostate Cancer May Improve Outcomes

Two Additions to Standard of Care in Prostate Cancer May Improve Outcomes

Long-term hormone monotherapy has been the standard of care for patients with PCa for more than 60 years. The purpose of this study was to compare the efficacy of 2 new treatment standards using a patient subset of the STAMPEDE trial.

Atezolizumab Improves Overall Survival Regardless of PD-L1 Expression in NSCLC

Atezolizumab Improves Overall Survival Regardless of PD-L1 Expression in NSCLC

The phase 3 OAK trial demonstrated that previously treated patients with advanced NSCLC experienced prolonged OS with atezolizumab compared to docetaxel regardless of PD-L1 status.

FLOT Combination Therapy May Be a New Standard for Esophageal Cancer

FLOT Combination Therapy May Be a New Standard for Esophageal Cancer

The relative effects of FLOT were demonstrable in all subgroups, and was pronounced numerically in patients with Barrett tumors, small tumors T1/2, nodal negative tumors, and Siewert type 1 esophageal tumors.

Similar Survival Benefit Observed in Both Simple and Extensive NSCLC Follow-up

Similar Survival Benefit Observed in Both Simple and Extensive NSCLC Follow-up

Although guidelines advocate follow-ups consisting of clinic visits and CT-scans, there is a lack of robust data supporting these recommendations.

Biosimilar and Reference Rituximab May Have Similar ORR in Follicular Lymphoma

Biosimilar and Reference Rituximab May Have Similar ORR in Follicular Lymphoma

Patients with untreated FL were randomly assigned to receive cyclophosphamide, vincristine, and prednisone (CVP) plus rituximab (R) or GP2013 for 8 cycles followed by 2 years of monotherapy maintenance in patients who responded to treatment.

Similar Efficacy, Less Toxicity with Neoadjuvant Letrozole/Palbociclib Versus Chemo in Breast Cancer

Similar Efficacy, Less Toxicity with Neoadjuvant Letrozole/Palbociclib Versus Chemo in Breast Cancer

Although there was less toxicity, neoadjuvant letrozole plus palbociclib had similar response and BCS rates when compared with chemotherapy.

BRCA2 Mutations Associated With Poor Outcomes in mCRPC

BRCA2 Mutations Associated With Poor Outcomes in mCRPC

Researchers find BRCA2 mutations are associated with worse outcomes among men with mCRPC.

Neoadjuvant Taselisib Combo Improves ORR in Early ER+/HER2- Breast Cancer

Neoadjuvant Taselisib Combo Improves ORR in Early ER+/HER2- Breast Cancer

This trial sought to determine if the letrozole and taselisib combination was effective in early-stage breast cancer.

Non-inferiority of Sorafenib-Pazopanib Sequence Not Reached in Renal Cell Carcinoma

Non-inferiority of Sorafenib-Pazopanib Sequence Not Reached in Renal Cell Carcinoma

The non-inferiority of the sorafenib (So) and pazopanib (Pa) sequence was not demonstrated compared to pazopanib-sorafenib in patients with metastatic renal cell carcinoma (mRCC).

Adding Pertuzumab Does Not Prolong Overall Survival in HER2+ Gastric or Gastro-esophageal Cancers

Adding Pertuzumab Does Not Prolong Overall Survival in HER2+ Gastric or Gastro-esophageal Cancers

Though a longer overall survival was observed in patients who received pertuzumab plus trastuzumab and chemotherapy, it was not statistically significant.

Cabozantinib and Nivolumab With or Without Ipilimumab May Be Effective in Genitourinary Cancers

Cabozantinib and Nivolumab With or Without Ipilimumab May Be Effective in Genitourinary Cancers

Cabozantinib and nivolumab (CaboNivo) with or without ipilimumab (Ipi) demonstrated manageable safety profiles and durable clinical activity.

First-Line Dose-Dense Chemo Fails to Prolong PFS in Ovarian Cancer

First-Line Dose-Dense Chemo Fails to Prolong PFS in Ovarian Cancer

First-line treatment failed to improve progression-free survival among women of European descent with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC).

Nivolumab plus RT and Temozolomide Tolerated in Glioblastoma

Nivolumab plus RT and Temozolomide Tolerated in Glioblastoma

First-line nivolumab plus radiotherapy (RT) with or without temozolomide was tolerated by patients with glioblastoma.

Sarcoma Resection at Expert Centers Associated With Better Outcomes

Sarcoma Resection at Expert Centers Associated With Better Outcomes

Surgical resection of soft tissue or visceral sarcoma conducted at an expert center resulted in substantially better outcomes compared with nonexpert centers.

Benefit of Binimetinib Addition to Encorafenib Confirmed in Melanoma

Benefit of Binimetinib Addition to Encorafenib Confirmed in Melanoma

Binimetinib a BRAF inhibitor, improved objective response rate (ORR) and progression-free survival (PFS) among patients with BRAF-mutant melanoma.

Adoptive Cellular Immunotherapy Improves Survival in Resected NSCLC

Adoptive Cellular Immunotherapy Improves Survival in Resected NSCLC

Adoptive cellular immunotherapy has not been widely used for cancer treatment.

Nivolumab Plus HPV-16 Vaccine are Promising in HPV-16+ Cancers

Nivolumab Plus HPV-16 Vaccine are Promising in HPV-16+ Cancers

Immune checkpoint inhibition may improve the efficacy of vaccine-induced T cells in incurable HPV genotype 16-positive cancer.

Pembrolizumab Shows Activity Among Some Young Patients With Advanced Sarcoma

Pembrolizumab Shows Activity Among Some Young Patients With Advanced Sarcoma

PD-1 inhibition with pembrolizumab may be an effective treatment option for adolescent and young adult patients with some sarcoma subtypes.

Potential Clinical Benefit in Multigene Hereditary Testing for Patients With Sarcoma

Potential Clinical Benefit in Multigene Hereditary Testing for Patients With Sarcoma

There may be potential clinical benefits to performing hereditary cancer risk assessments and multi-gene panel testing in patients with sarcoma.

Talimogene Laherparepvec Plus Ipilimumab Promising for Advanced Melanoma

Talimogene Laherparepvec Plus Ipilimumab Promising for Advanced Melanoma

Talimogene laherparepvec plus ipilimumab improves the overall response rate over ipilimumab alone among patients with unresected, advanced melanoma.

In Focus: Abemaciclib for Advanced Breast Cancer

In Focus: Abemaciclib for Advanced Breast Cancer

Several presentations demonstrated that abemaciclib provides clinical benefit for women with HR+/HER2-negative breast cancer who progress on or are resistant to endocrine therapy.

Future Treatment Modalities in Sarcoma: Insights From ASCO 2017

Future Treatment Modalities in Sarcoma: Insights From ASCO 2017

Targeted and immunotherapeutic approaches are poised to change how sarcoma will be treated in the future. Trials are being used to match tumors with appropriate treatment choices.

Overcoming Drug Resistance in the Treatment of Metastatic Breast Cancer

Overcoming Drug Resistance in the Treatment of Metastatic Breast Cancer

The management of metastatic breast cancer resistant or refractory to hormonal treatments, while still challenging, is rapidly improving.

Maintenance Pembrolizumab Does Not Improve PFS in Small-cell Lung Cancer

Maintenance Pembrolizumab Does Not Improve PFS in Small-cell Lung Cancer

Maintenance pembrolizumab does not prolong progression-free survival, though it may improve overall survival, among patients with extensive-stage small-cell lung cancer.

Afatinib Not Recommended Post-CRT for Patients With Squamous Cell Carcinoma of the Head and Neck

Afatinib Not Recommended Post-CRT for Patients With Squamous Cell Carcinoma of the Head and Neck

Adding afatinib to standard CRT is not recommended for patients with primary unresected, high- or intermediate-risk HNSCC.

Momelotinib vs Ruxolitinib for Patients With Myelofibrosis

Momelotinib vs Ruxolitinib for Patients With Myelofibrosis

Momelotinib, an oral JAK inhibitor, is non-inferior to ruxolitinib in reducing spleen volume, though not for improving disease-related symptoms, among patients with myelofibrosis.

Aldoxorubicin: A Way Forward for Soft Tissue Sarcoma?

Aldoxorubicin: A Way Forward for Soft Tissue Sarcoma?

Although aldoxorubicin did not improve OS, the available evidence suggests that it is nevertheless superior to doxorubicin — particularly among patients with liposarcoma and leiomyosarcoma.

Eighteen-month ADT Plus RT Recommended Standard for Patients With High-risk Prostate Cancer

Eighteen-month ADT Plus RT Recommended Standard for Patients With High-risk Prostate Cancer

Reducing the duration of androgen-deprivation therapy with radiation therapy from 36 months to 18 months is safe for patients with high-risk prostate cancer.

Docetaxel Plus Cyclophosphamide Non-inferior to Anthracycline-based Chemotherapy in Breast Cancer

Docetaxel Plus Cyclophosphamide Non-inferior to Anthracycline-based Chemotherapy in Breast Cancer

Patients with early stage, HER2-negative breast cancer may be sufficiently well-treated with docetaxel and cyclophosphamide instead of anthracycline-based chemotherapy.

Engagement Is Survival: My Take on ASCO 2017

Engagement Is Survival: My Take on ASCO 2017

Don Dizon, MD: In addition to important clinical trial outcomes that evaluated novel strategies across tumor types, there were impressive studies aiming to help our patients live with cancer as well.

aBSI Is of Prognostic Significance in Castration-resistant Prostate Cancer

aBSI Is of Prognostic Significance in Castration-resistant Prostate Cancer

An automated bone scan index at baseline is clinically validated as a prognostic biomarker in men with castration-resistant prostate with bone metastases.

Less Than A Quarter of Patients With CLL Tested for IGHV Mutation Prior to Initial Therapy

Less Than A Quarter of Patients With CLL Tested for IGHV Mutation Prior to Initial Therapy

Only 21% of patients underwent IGHV mutation-testing prior to initiating bendamustine plus rituximab therapy; 46% of tested patients were IGHV-mutated.

Q&A With Narjust Duma, MD: Minority Patient Participation in Breast Cancer Clinical Trials

Q&A With Narjust Duma, MD: Minority Patient Participation in Breast Cancer Clinical Trials

In this question-and-answer session, Cancer Therapy Advisor asked Dr Duma about her team's study and minority patient representation in breast cancer studies.

Bevacizumab Improves PFS, But Not OS, When Combined With Chemotherapy in SCCHN

Bevacizumab Improves PFS, But Not OS, When Combined With Chemotherapy in SCCHN

Bevacizumab added to a standard platinum doublet chemotherapy regimen did not improve OS, though PFS was improved, among patients with cancer of the head and neck.

Intermittent Letrozole May Benefit Some Patients With Breast Cancer

Intermittent Letrozole May Benefit Some Patients With Breast Cancer

Study data suggest that some women with breast cancer may benefit from intermittent over continuous letrozole treatment.

FLOT Is Superior to ECF/ECX Among Patients With Gastric Cancer

FLOT Is Superior to ECF/ECX Among Patients With Gastric Cancer

Perioperative FLOT significantly improved PFS and OS among patients with resectable gastric cancers compared with standard ECF/ECX.

Pembrolizumab Active in Advanced Gastric Cancer

Pembrolizumab Active in Advanced Gastric Cancer

Pembrolizumab monotherapy showed clinical efficacy in patients with advanced gastric cancer.

Advanced Renal Cell Carcinoma: Interviews With Neeraj Agarwal, MD, and Ulka Vaishampayan, MD

Advanced Renal Cell Carcinoma: Interviews With Neeraj Agarwal, MD, and Ulka Vaishampayan, MD

Ulka Vaishampayan, MD, and Neeraj Agarwal, MD, spoke with Cancer Therapy Advisor about treatment recommendations for patients newly diagnosed with metastatic RCC.

High Activity for Nivolumab Alone and With Ipilimumab in Small-cell Lung Cancer

High Activity for Nivolumab Alone and With Ipilimumab in Small-cell Lung Cancer

Nivolumab alone or combined with ipilimumab provided durable responses in patients with advanced small-cell lung cancer whose disease progressed on prior platinum therapies.

Bosutinib vs Imatinib for First-line Chronic Myeloid Leukemia Treatment

Bosutinib vs Imatinib for First-line Chronic Myeloid Leukemia Treatment

Data from the BFORE study showed significantly higher 12-month major molecular remission and complete cytogenetic response with bosutinib.

Momelotinib for Previously Treated Patients With Myelofibrosis

Momelotinib for Previously Treated Patients With Myelofibrosis

For patients with primary or secondary myelofibrosis who have already received ruxolitinib, momelotinib was significant in improving disease-related symptoms over best available therapy.

Dabrafenib Plus Trametinib Promising in Melanoma

Dabrafenib Plus Trametinib Promising in Melanoma

Patients with BRAF V600E melanoma and brain metastasis showed intracranial responses when receiving a BRAF (dabrafenib) and a MEK inhibitor (trametinib).

Adding Veliparib to Doublet Chemotherapy Improves PFS in Small-cell Lung Cancer

Adding Veliparib to Doublet Chemotherapy Improves PFS in Small-cell Lung Cancer

Veliparib added to cisplatin and etoposide improves progression-free survival among patients with extensive stage small-cell lung cancer.

Three-month XELOX Regimen May Be Non-inferior to 6-month Regimen in Colorectal Cancer

Three-month XELOX Regimen May Be Non-inferior to 6-month Regimen in Colorectal Cancer

An analysis suggested that a shorter, 3-month course of adjuvant chemotherapy for some patients with stage III colon cancer may yield comparable outcomes to the standard 6-month course.

Olaparib is Efficacious in BRCA-related Metastatic Breast Cancer

Olaparib is Efficacious in BRCA-related Metastatic Breast Cancer

Patients with a germline BRCA mutation were at a reduced risk for progression when treated with olaparib for HER2-metastatic breast cancer.

Nivolumab With Ipilimumab May Negate Need for Whole Brain Radiotherapy in Melanoma With Brain Metastases

Nivolumab With Ipilimumab May Negate Need for Whole Brain Radiotherapy in Melanoma With Brain Metastases

Combination immunotherapy with nivolumab and ipilimumab provided intracranial and extracranial responses for patients with melanoma and brain metastases.

Immunotherapy Shows Promise in Patients With Melanoma Brain Metastases

Immunotherapy Shows Promise in Patients With Melanoma Brain Metastases

Nivolumab alone or in combination with ipilimumab were reported to show activity in patients with melanoma and asymptomatic brain metastases.

Establishing a Short-term Response Endpoint for mCRPC Trials

Establishing a Short-term Response Endpoint for mCRPC Trials

After looking at 8 short-term endpoints based on PSA and CTCs, absence of tumor cells at week 13 was considered the best predictor of overall survival.

Dual HER2 Blockade Superior in HER2+ HR+ Breast Cancer

Dual HER2 Blockade Superior in HER2+ HR+ Breast Cancer

When combined with an aromatase inhibitor, dual HER2 blockade shows superior PFS compared with lapatinib or trastuzumab alone in some women with breast cancer.

MARIANNE Update: T-DM1 Does Not Significantly Improve Survival in HER2+ Breast Cancer

MARIANNE Update: T-DM1 Does Not Significantly Improve Survival in HER2+ Breast Cancer

The antibody drug conjugate, T-DM1, when used alone or in combination with pertuzumab, did not significantly improve overall survival compared with trastuzumab and a taxane.

TREnd: Adding Palbociclib to Endocrine Therapy Provides Clinical Benefits in Breast Cancer

TREnd: Adding Palbociclib to Endocrine Therapy Provides Clinical Benefits in Breast Cancer

Evidence suggests that combining palbociclib with endocrine therapy can reverse acquired resistance to endocrine therapy in breast cancer.

Electronic Patient-reported Outcome System Improves Survival Among Patients With Cancer

Electronic Patient-reported Outcome System Improves Survival Among Patients With Cancer

A study showed that symptom monitoring by integrating electronic patient-reported outcomes into clinical practice vs usual care extended OS by more than 5 months.

PALOMA-1 Update: Survival With Palbociclib Not Significantly Improved in ER+/HER2- Breast Cancer

PALOMA-1 Update: Survival With Palbociclib Not Significantly Improved in ER+/HER2- Breast Cancer

Data from PALOMA-1/TRIO-18 showed that combining palbociclib and letrozole did not significantly improve survival compared with letrozole alone among patients with breast cancer.

Abemaciclib Plus Fulvestrant Is Effective Therapy in Endocrine-resistant Breast Cancer

Abemaciclib Plus Fulvestrant Is Effective Therapy in Endocrine-resistant Breast Cancer

Patients with breast cancer who progress on endocrine therapy and are then treated with abemaciclib and fulvestrant have a 45% decreased risk for progression.

Vemurafenib Active in BRAFV600-mutant NSCLC

Vemurafenib Active in BRAFV600-mutant NSCLC

Vemurafenib improves outcomes among patients with non-small cell lung cancer with a BRAFV600 mutation.

Aldoxorubicin Improves Outcomes in Relapsed/Refractory Sarcoma

Aldoxorubicin Improves Outcomes in Relapsed/Refractory Sarcoma

Aldoxorubicin significantly prolongs PFS and provides better objective response rates than investigators' choice of treatment or standard of care in the treatment of soft tissue sarcoma.

Korean Red Ginseng Improves Cancer-related Fatigue in Colorectal Cancer

Korean Red Ginseng Improves Cancer-related Fatigue in Colorectal Cancer

Consuming Korean red ginseng was reported to improve cancer-related fatigue among Korean patients with colorectal cancer (CRC) treated with FOLFOX.

Promising Activity Reported for Nivolumab in Gynecologic Cancers

Promising Activity Reported for Nivolumab in Gynecologic Cancers

Nivolumab, a programmed death (PD)-1 inhibitor, showed promising clinical activity in recurrent or metastatic cervical cancers and provides a promising new approach to treatment.

Sarcoma: Next-generation Sequencing Has Implications for Diagnosis and Treatment

Sarcoma: Next-generation Sequencing Has Implications for Diagnosis and Treatment

A retrospective analysis of next-generation sequencing profiles has diagnostic and therapeutic implications for patients with soft-tissue or bone sarcoma.

Personalizing Care for Patients With Sarcoma

Personalizing Care for Patients With Sarcoma

The landscape of complex genetic mutations in sarcomas seen through next-generation sequence profiling provides a rationale for a study to match patients to the appropriate therapy.

Endometrial Cancer: Adjuvant Taxane Plus Platinum Agent Does Not Improve Outcomes

Endometrial Cancer: Adjuvant Taxane Plus Platinum Agent Does Not Improve Outcomes

A study concluded that adjuvant therapy with a taxane and a platinum agent was not superior over standard therapy for women with high-risk endometrial cancer.

Yoga Improves Sleep Disorders, Fatigue in Patients With Cancer

Yoga Improves Sleep Disorders, Fatigue in Patients With Cancer

Improvements in cancer-related fatigue from yoga were linked to improvements in sleep quality and daytime dysfunction.

Toxicity-driven Sunitinib Dosing Improves Outcomes in RCC

Toxicity-driven Sunitinib Dosing Improves Outcomes in RCC

Toxicity-driven dosing of sunitinib improved response rates and survival compared with historical standard dosing among patients with metastatic renal cell carcinoma.

Plasma HGF Levels During Treatment Prognostic for Survival in RCC

Plasma HGF Levels During Treatment Prognostic for Survival in RCC

Patients with a decline in HGF levels had longer overall survival than those with high levels at baseline and at 4 weeks.

Two-to-One Sunitinib Schedule Fails To Reduce Toxicity

Two-to-One Sunitinib Schedule Fails To Reduce Toxicity

A modified dosing schedule of sunitinib did not improve adverse events rates among patients with metastatic renal cell carcinoma.

Pembrolizumab Active in Few Soft Tissue, Bone Sarcoma Subtypes

Pembrolizumab Active in Few Soft Tissue, Bone Sarcoma Subtypes

Pembrolizumab shows antitumor activity in osteosarcoma and undifferentiated pleomorphic sarcoma, but not other types of soft tissue sarcomas.

Cabozantinib Evaluated in Aggressive Endometrial Cancer Subtype

Cabozantinib Evaluated in Aggressive Endometrial Cancer Subtype

Cabozantinib may have activity in carcinosarcoma and warrants further investigation.

Do Specialized Cancer Centers Improve Outcomes for Patients With Ewing Sarcoma?

Do Specialized Cancer Centers Improve Outcomes for Patients With Ewing Sarcoma?

Patients with Ewing sarcoma aged 19 to 39 years may benefit from treatment at a specialized cancer center.

Young Patients With CLL At Risk for Secondary Cancers

Young Patients With CLL At Risk for Secondary Cancers

Patients with chronic lymphocytic leukemia younger than age 55 are at an increased risk for multiple types of secondary cancers for up to 15 years after diagnosis.

Ibrutinib Provides Long-term Benefits for Patients With CLL

Ibrutinib Provides Long-term Benefits for Patients With CLL

Ibrutinib provides long term survival benefits to patients with chronic lymphocytic leukemia regardless of cytogenetic risk factors.

Durable PFS With Fludarabine, Rituximab, and Lenalidomide in CLL

Durable PFS With Fludarabine, Rituximab, and Lenalidomide in CLL

Fludarabine and rituximab plus lenalidomide results in durable prolonged PFS compared with FR or FR plus cyclophosphamide among patients with untreated chronic lymphocytic leukemia.

Cediranib Prolongs Progression-free Survival in Alveolar Soft Part Sarcoma

Cediranib Prolongs Progression-free Survival in Alveolar Soft Part Sarcoma

Data suggest that cediranib-treatment of ASPS results in a substantial reduction in tumor burden and prolonged PFS.

Regorafenib Clinically Active in Ewing Sarcoma

Regorafenib Clinically Active in Ewing Sarcoma

SARC024 study met its primary endpoint for patients with Ewing sarcoma, and enrollment is ongoing for the liposarcoma and osteosarcoma cohorts.

Pazopanib Active in Malignant/Dedifferentiated SFT

Pazopanib Active in Malignant/Dedifferentiated SFT

Pazopanib showed antitumor efficacy among patients with unresectable or metastatic malignant/dedifferentiated soft fibrous tumors.

Affordable Care Act Increased Rate of Early Cancer Diagnoses

Affordable Care Act Increased Rate of Early Cancer Diagnoses

The US Affordable Care Act may have increased the proportion of patients with cancer diagnosed at stage I, according to a study.

Adjuvant Gefitinib Prolongs Disease-free Survival in Non-small Cell Lung Cancer

Adjuvant Gefitinib Prolongs Disease-free Survival in Non-small Cell Lung Cancer

Adjuvant gefitinib significantly prolongs disease-free survival compared with vinorelbine plus cisplatin among patients with stage II to III non-small cell lung cancer.

Interprofessional Teams To Improve Oncology Care

Interprofessional Teams To Improve Oncology Care

Interprofessional practice provides benefits to patients, team members, and the health care system, by working collaboratively to support and assist each other.

Nilotinib Associated With Treatment-induced T2DM and Hyperlipidemia

Nilotinib Associated With Treatment-induced T2DM and Hyperlipidemia

This study suggest that nilotinib is associated with higher rates of treatment-induced T2DM and hyperlipidemia compared with dasatinib.

No Difference in Aprepitant vs Fosaprepitant in CINV

No Difference in Aprepitant vs Fosaprepitant in CINV

This study indicates that there is no difference in efficacy or safety between aprepitant and fosaprepitant, though the study was limited by its small sample size.

Facing Ethical Dilemmas in Oncology

Facing Ethical Dilemmas in Oncology

Oncology clinicians face ethical dilemmas regarding access to care and treatments, palliative and end-of-life care, and treating vulnerable populations in today's clinical environment.

Four New Drugs Approved for Multiple Myeloma Since 2015

Four New Drugs Approved for Multiple Myeloma Since 2015

Four new agents were approved for relapsed/refractory multiple myeloma (RRMM) since 2015, providing more options but adding complexity to the treatment of this disease.

Lanreotide Effective Regardless of Prior Octreotide in Carcinoid Syndrome

Lanreotide Effective Regardless of Prior Octreotide in Carcinoid Syndrome

Lanreotide depot is effective among patients with or without previous octreotide treatment for carcinoid syndrome.

Single-nucleotide Polymorphisms Predict Response to R-CHOP in DLBCL

Single-nucleotide Polymorphisms Predict Response to R-CHOP in DLBCL

Two SNPS (rs4880 and rs1870377) had an association with PFS among patients with DLBCL receiving R-CHOP.

Steroid-containing Chemotherapy Can Induce Diabetes in DLBCL

Steroid-containing Chemotherapy Can Induce Diabetes in DLBCL

Glucocorticoid-containing chemotherapy may induce diabetes mellitus or worsen glucose control among patients with diffuse large B cell lymphoma.

2016 Oncology Drug Approvals Span Multiple Cancers

2016 Oncology Drug Approvals Span Multiple Cancers

At the 2017 HOPA Annual Conference, Vivian Park, PharmD, MBA, BCOP, discussed agents approved by the FDA in oncology in 2016.

Oncology Treatment and Care, The Role of Value-based Frameworks

Oncology Treatment and Care, The Role of Value-based Frameworks

Multiple value frameworks were developed to help providers, institutions, and payers determine the value of cancer treatment.

ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer

ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer

In an indirect comparison, brigatinib appeared to have greater efficacy than alectinib or ceritinib in ALK+ non-small cell lung cancer.

Durable Responses With Single-agent Ibrutinib in CLL/SLL

Durable Responses With Single-agent Ibrutinib in CLL/SLL

A study suggests that single-agent ibrutinib results in durable responses among patients with CLL or SLL.

Myeloma Patients Not Receiving Guideline-recommended Thromboprophylaxis

Myeloma Patients Not Receiving Guideline-recommended Thromboprophylaxis

Data suggest that most patients with MM taking immunomodulatory therapy are not receiving appropriate thromboprophylaxis.

Leflunomide May Effectively Treat CMV After Allogeneic-HSCT

Leflunomide May Effectively Treat CMV After Allogeneic-HSCT

The findings of this study suggest that leflunomide may be an effective treatment of CMV infection among patients who have received allo-HSCT.

Patient Burden Related to Off-Label Prescribing in Sarcoma

Patient Burden Related to Off-Label Prescribing in Sarcoma

Data suggest that off-label prescribing may increase the time to treatment receipt, but may lower costs for patients.

Hypermethylation of DNA Repair Genes in Ovarian Carcinoma

Hypermethylation of DNA Repair Genes in Ovarian Carcinoma

Hypermethylation of HRR-associated genes was not associated with improved survival in ovarian cancer.

Sentinel Lymph Node Mapping Cost-effective in Endometrial Carcinoma

Sentinel Lymph Node Mapping Cost-effective in Endometrial Carcinoma

Study data suggest that SLN mapping is more cost-effective and more efficacious than routine LND or selective LND.

Elderly Patients and Treatment Tolerance in Phase 1 Trials

Elderly Patients and Treatment Tolerance in Phase 1 Trials

Study results suggest that carefully selected elderly patients with recurrent or refractory gynecologic malignancy should be enrolled in phase 1 trials.

Patients With Ovarian Cancer Rank Nausea as Most Concerning Chemotherapy Side Effect

Patients With Ovarian Cancer Rank Nausea as Most Concerning Chemotherapy Side Effect

Patients with newly diagnosed ovarian cancer rank nausea as the most concerning side effect associated with chemotherapy.

Combined Liquid Pap and CT-DNA Testing May Detect Ovarian Cancer

Combined Liquid Pap and CT-DNA Testing May Detect Ovarian Cancer

Combined liquid-based Pap and CT-DNA may be a new method for tumor-derived driver mutation screening in primary ovarian carcinoma.

Reduction Strategies Improve Surgical Site Infection Rate After Colon Surgery

Reduction Strategies Improve Surgical Site Infection Rate After Colon Surgery

The results of this study show that implementation of strategies to reduce SSI can improve SSI rates, despite risk factors for infection.

Chemotherapy Fails To Prolong Survival in Low-grade Serous Ovarian Cancer

Chemotherapy Fails To Prolong Survival in Low-grade Serous Ovarian Cancer

Adjuvant platinum-based chemotherapy did not improve survival in women with low-grade serous ovarian cancer.

Adjuvant Chemotherapy Without Radiation Effective in Stage IB-IIA Cervical Cancer

Adjuvant Chemotherapy Without Radiation Effective in Stage IB-IIA Cervical Cancer

Data suggest that adjuvant chemotherapy without radiation may be an effective option for patients with stage IB to IIA cervical cancer with risk factors.

Adding Whole Pelvic Radiation to Chemotherapy May Prolong Survival in Advanced Cervical Cancer

Adding Whole Pelvic Radiation to Chemotherapy May Prolong Survival in Advanced Cervical Cancer

Data indicate that the addition of WPR to chemotherapy may provide a survival benefit, though prospective studies are needed to confirm these findings.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters